Biocon is focused on developing cutting edge intellectual property as a core value differentiator. Biocon’s patent portfolio totals close to 800 applications worldwide with over 130 granted patents; covering technology areas of fermentation, protein purification, drug delivery systems and biotherapeutic molecules. IP analysis is a tool used to actively support R&D and marketing in its scientific quest and marketing strategies respectively. As Biocon continues to strengthen its knowledge base in small molecules, recombinant proteins and antibodies, through co-development and research collaborations with strategic global partners, the IP generated is either shared or owned by Biocon. Adequate protection of the intellectual output generated by R&D entails strategic decisions for filing patents at the appropriate time and place with effective cost benefit ratio. The commercial potential of this intangible asset is harnessed by licensing opportunities and its exclusive use.